Clinical Trial Update: Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS [Phase 4]

View source ↗

Summary

Phase 4 post-marketing clinical trial evaluating ravulizumab in patients with atypical Hemolytic Uremic Syndrome (aHUS) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: aHUS, Atypical Hemolytic Uremic Syndrome | Phase 4 | Status: RECRUITING